openPR Logo
Press release

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7)-Pipeline Review, H2 2017

10-24-2017 08:43 AM CET | Industry, Real Estate & Construction

Press release from: Market Research Hub

Market Research HUB

Market Research HUB

Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Glutamyl Aminopeptidase Pipeline Review, H2 2017”, report provides Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The latest report Glutamyl Aminopeptidase - Pipeline Review, H2 2017, outlays comprehensive information on the Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Request For Free Sample Report: https://www.marketresearchhub.com/enquiry.php?type=S&repid=1350038

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Glutamyl aminopeptidase is an enzyme encoded by the ENPEP gene. It is a zinc-dependent membrane-bound aminopeptidase that catalyzes the cleavage of glutamatic and aspartatic amino acid residues from the N-terminus of polypeptides. The enzyme degrades vasoconstricting angiotensin II into angiotensin III and helps to regulate blood pressure. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Report covers products from therapy areas Cardiovascular, Oncology and Women's Health which include indications Hypertension, Congestive Heart Failure (Heart Failure), Endometriosis, Hepatic (Liver) Tumor, Idiopathic (Essential) Hypertension, Left Ventricular Dysfunction, Neuroblastoma and Resistant Hypertension.

Furthermore, this report also reviews key players involved in Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7)
- The report reviews Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Browse Full Report with TOC: https://www.marketresearchhub.com/report/glutamyl-aminopeptidase-eap-or-aminopeptidase-a-or-differentiation-antigen-gp160-or-cd249-or-enpep-or-ec-34117-pipeline-review-h2-2017-report.html

Table of Content:
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Overview 6
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Therapeutics Assessment 12
Assessment by Mechanism of Action 12
Assessment by Route of Administration 13
Assessment by Molecule Type 14
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Companies Involved in Therapeutics Development 16
APAvadis Biotechnologies Srl 16
Quantum Genomics SA 17
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Drug Profiles 18
Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
QGC-001 - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
QGC-006 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
QGC-011 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
QGC-101 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Product Development Milestones 26
Featured News & Press Releases 26
Continue….

Enquire About This Report: https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1350038

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States

Toll Free: 800-998-4852 (US-Canada)
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7)-Pipeline Review, H2 2017 here

News-ID: 782428 • Views: 203

More Releases from Market Research Hub

Acrylate Polymers Market Share, Industry Analysis & Forecast Report 2019-2025
Market Research Hub (MRH) has actively uploaded a smart research report titled “Global Acrylate Polymers Market Professional Survey Report 2019”, to its broad online database. The primary motive of this study is to impart vital details associated to development of the Acrylate Polymers Market. The assessment includes brief knowledge about market size, Y-o-Y growth, market dynamics and competitive scenario expected to transform in the near future. Ever section of the
Abrasive Wheels & Discs Market Drivers, Segment by Regions and Growth Analysis, …
Market Research Hub (MRH) has recently uploaded a new study titled “Global Abrasive Wheels & Discs Market Professional Survey Report 2019” to its broad online storehouse. The global Abrasive Wheels & Discs Market conveniently covers prime factors motivating development and steering industry trends and demand scenarios. Readers can easily quantify market opportunities with the availability of information such as market sizing and market forecasting, thereby being able to analyze the
Oral Dosing Cups Market Analysis By Application 2025 | Top Players- Comar, Inc, …
Market Research Hub (MRH) has actively uploaded a smart research report titled “Global Oral Dosing Cups Market Insights, Forecast to 2025”, to its broad online database. The primary motive of this study is to impart vital details associated to development of the Oral Dosing Cups market. The assessment includes brief knowledge about market size, Y-o-Y growth, market dynamics and competitive scenario expected to transform in the near future. Ever section
Opthalmic Lenses Market 2019-2025|Major Players- ZEISS, HOYA, SHIMIZU, Rodenstoc …
Market Research Hub (MRH) has actively uploaded a smart research report titled “Global Opthalmic Lenses Market Insights, Forecast to 2025”, to its broad online database. The primary motive of this study is to impart vital details associated to development of the Opthalmic Lenses market*. The assessment includes brief knowledge about market size, Y-o-Y growth, market dynamics and competitive scenario expected to transform in the near future. Ever section of the

All 5 Releases